We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+37.28%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$959M
AUM Growth
+$88.6M
Cap. Flow
-$54.3M
Cap. Flow %
-5.67%
Top 10 Hldgs %
33.04%
Holding
103
New
15
Increased
39
Reduced
35
Closed
12

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$17.6M
2
BSX icon
Boston Scientific
BSX
+$15.7M
3
KALV
KalVista Pharmaceuticals
KALV
+$14.6M
4
MCK icon
McKesson
MCK
+$7.81M
5
FOLD
Amicus Therapeutics
FOLD
+$7.68M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$18.7M
2
LLY icon
Eli Lilly
LLY
+$17.3M
3
THC icon
Tenet Healthcare
THC
+$16.8M
4
RVTY icon
Revvity
RVTY
+$15.2M
5
COO icon
Cooper Companies
COO
+$14.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VERA icon
76
Vera Therapeutics
VERA
$2.16B
$2.81M 0.29%
96,737
-19,606
-17% -$453K
DVAX
77
DELISTED
Dynavax Technologies
DVAX
$2.69M 0.28%
271,306
+1,175
+0.4% +$12.2K
TVRD
78
Tvardi Therapeutics
TVRD
$22.1M
$2.53M 0.26%
+65,000
New +$1.85M
SLDB icon
79
Solid Biosciences
SLDB
$971M
$2.45M 0.26%
+396,396
New +$2.32M
DAWN
80
DELISTED
Day One Biopharmaceuticals
DAWN
$2.13M 0.22%
301,746
-198,254
-40% -$1.36M
RARE icon
81
Ultragenyx Pharmaceutical
RARE
$2.65B
$2.06M 0.22%
68,636
-79,344
-54% -$2.38M
FDMT icon
82
4D Molecular Therapeutics
FDMT
$621M
$1.74M 0.18%
+200,000
New +$1.2M
QTRX icon
83
Quanterix
QTRX
$139M
$1.37M 0.14%
252,211
-263,781
-51% -$1.4M
ANNX icon
84
Annexon
ANNX
$873M
$1.24M 0.13%
405,953
+1,759
+0.4% +$4.37K
BFLY icon
85
Butterfly Network
BFLY
$2.52B
$1.16M 0.12%
+602,192
New +$1.02M
MASS icon
86
908 Devices
MASS
$414M
$879K 0.09%
100,368
+368
+0.4% +$2.44K
LUNG icon
87
Pulmonx
LUNG
$98.4M
$811K 0.08%
500,662
-104,367
-17% -$218K
CMPS
88
Compass Pathways
CMPS
$1.97B
$573K 0.06%
+100,000
New +$449K
ENTX icon
89
Entera Bio
ENTX
$138M
$539K 0.06%
280,822
-75,000
-21% -$144K
FOCL
90
EDAP TMS S.A.
FOCL
$178M
$355K 0.04%
154,832
– –
OVID icon
91
Ovid Therapeutics
OVID
$489M
$264K 0.03%
+202,978
New +$176K
ALKS icon
92
PUT
Alkermes
ALKS
$8.44B
– –
-200,000
Closed -$5.72M
ANIP icon
93
ANI Pharmaceuticals
ANIP
$1.73B
– –
-128,478
Closed -$8.38M
ARDX icon
94
Ardelyx
ARDX
$1.03B
– –
-301,086
Closed -$1.18M
DGX icon
95
Quest Diagnostics
DGX
$26.2B
– –
-40,997
Closed -$7.36M
GILD icon
96
Gilead Sciences
GILD
$168B
– –
-131,675
Closed -$14.6M
MRUS
97
DELISTED
Merus
MRUS
– –
-162,980
Closed -$8.57M
NRIX icon
98
Nurix Therapeutics
NRIX
$2.76B
– –
-228,271
Closed -$2.6M
REPL icon
99
Replimune Group
REPL
$1.28B
– –
-896,710
Closed -$8.33M
RVTY icon
100
Revvity
RVTY
$13.2B
– –
-157,196
Closed -$15.2M
1 2 3
4
5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Parkman Healthcare Partners held 103 positions worth $959M, up 10% from $870M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Parkman Healthcare Partners withdrew a net $54.3M in Q3 2025, closing 12 positions and reducing 35 holdings. Its most notable exit was Verona Pharma, an estimated $18.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 99% a quarter earlier.

Against the trend, Parkman Healthcare Partners opened a new position in Biogen worth $18.2M.

  • Parkman Healthcare Partners's largest Q3 2025 buy was Biogen: 130,165 shares worth $18.2M.
  • Parkman Healthcare Partners added most to Boston Scientific in Q3 2025, an estimated $15.7M increase.
  • Parkman Healthcare Partners's biggest Q3 2025 reduction was Eli Lilly, cutting an estimated $17.3M.
  • Parkman Healthcare Partners fully exited Verona Pharma in Q3 2025, selling an estimated $18.7M.
  • Parkman Healthcare Partners's ten largest holdings make up 33% of its $959M portfolio in Q3 2025.
  • Parkman Healthcare Partners opened 15 new positions and closed 12 in Q3 2025.
  • Parkman Healthcare Partners's portfolio value rose 10% quarter-over-quarter to $959M.

Based on Parkman Healthcare Partners's 13F filing for Q3 2025, filed 14 Nov 2025.